克感利咽口服液治疗急性咽炎的疗效与安全性:随机双盲安慰剂对照多中心试验
该研究为随机双盲安慰剂对照多中心试验,纳入239例急性咽炎患者,评估克感利咽口服液共5天的疗效与安全性。结果显示第6天恢复率显著高于安慰剂组,咽痛与咳嗽VAS评分改善更明显,咽痛恢复时间缩短,中医证候积分下降,且安全耐受。
要点
- 克感利咽口服液可提高急性咽炎第6天恢复率并缓解咽痛、咳嗽等症状。
- 该药缩短咽痛恢复时间,且未增加对乙酰氨基酚使用。
- 研究显示克感利咽口服液安全且耐受性良好。
核心结论
- 克感利咽口服液可能是急性咽炎有益且安全的替代治疗,可缓解咽痛、咽肿、咳嗽和咳痰等症状。
研究设计与样本
- 随机、双盲、安慰剂对照、多中心研究,来自17家医院的参与者按1:1随机分配接受克感利咽口服液或安慰剂治疗5天。
- 共纳入239例参与者(克感利咽组120例,安慰剂组119例),在基线、第3天和第6天进行评估。
主要发现
- 第6天恢复率克感利咽组显著更高,组间差异为27.20%[15.00%至39.40%],p<0.001。
- 第3天和第6天,克感利咽组咽痛VAS评分较基线下降更大(-3.02 vs -2.37,p=0.001;-4.66 vs -3.64,p<0.001),咳嗽VAS评分下降也更大(-1.55 vs -1.05,p=0.004;-2.28 vs -1.56,p<0.001)。
- 克感利咽口服液降低了咽痛VAS评分的AUC(-2.33[-4.10至-0.56],p=0.011),缩短了咽痛恢复时间(风险比0.42[0.30至0.59],p<0.001),提高了第6天咽痛恢复率(75.00% vs 42.86%,p<0.001),降低了中医证候积分(-2.03[-2.69至-1.37],p<0.001),并改善了个别中医症状。
- 两组对乙酰氨基酚使用量无显著差异,克感利咽口服液安全且耐受。
临床怎么用
- 对于急性咽炎患者,可考虑使用克感利咽口服液作为缓解咽痛、咳嗽等症状的替代治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alleviating the sore throat caused by acute pharyngitis is a primary patient concern. However, antibiotics are not commonly recommended drugs, and abuse can lead to serious consequences such as drug resistance. Therefore, seeking alternative treatments is necessary. PURPOSE: To investigate the efficacy and safety of Kegan Liyan (KGLY) oral liquid for patients with acute pharyngitis. STUDY DESIGN: Randomized, double-blinded, placebo-controlled, multi-center study. METHODS: Participants from 17 hospitals were randomly assigned 1:1 to receive KGLY oral liquid or placebo for five days. Assessments occurred at baseline, day 3, and day 6. The primary outcome was the recovery rate. Secondary outcomes included sore throat and cough visual analogue scale (VAS), the area under the curve (AUC) of sore throat VAS, time to sore throat relief and recovery, proportion of participants with sore throat relief and recovery, traditional Chinese medicine (TCM) syndrome score, single TCM manifestation score and use of acetaminophen. RESULTS: Involving 239 participants (120 in KGLY and 119 in placebo group), the study found a significantly higher recovery rate on day 6 in the KGLY group (between-group difference, 27.20 % [15.00 % to 39.40 %], p < 0.001). On day 3 and 6, the KGLY group showed significantly larger reductions in sore throat (-3.02 vs -2.37, p = 0.001; -4.66 vs -3.64, p < 0.001) and cough VAS scores (-1.55 vs -1.05, p = 0.004; -2.28 vs -1.56, p < 0.001) from baseline. KGLY oral liquid lowered the AUC of sore throat VAS score (-2.33 [-4.10 to -0.56], p = 0.011), shortened time to sore throat recovery (hazard ratio, 0.42 [0.30 to 0.59], p < 0.001), increased sore throat recovery rate at day 6 (75.00 % vs 42.86 %, p < 0.001), decreased the TCM syndrome score (-2.03 [-2.69 to -1.37], p < 0.001), and improved individual TCM symptoms compared to placebo. No significant differences between the groups in acetaminophen usage. KGLY oral liquid was safe and tolerated. CONCLUSION: KGLY oral liquid may be a beneficial and safe alternative treatment for acute pharyngitis, which can alleviate symptoms such as sore throat, swollen throat, cough, and phlegm production.
引用
- Lin L, Xiao J, Wu L, et al. Efficacy and safety of Kegan Liyan oral liquid for patients with acute pharyngitis: A randomized, double-blinded, placebo-controlled, multi-center trial. Phytomedicine. 2024. PMID: 39217655. doi:10.1016/j.phymed.2024.155960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。